Human Immunoglobulin G
| Evidence Level: L4 | Predicted Indications: 3 |
Table of Contents
- Human Immunoglobulin G
- Human Immunoglobulin G: From Approved Immunoglobulin Products to Severe Nonproliferative Diabetic Retinopathy
Human Immunoglobulin G: From Approved Immunoglobulin Products to Severe Nonproliferative Diabetic Retinopathy
One-Sentence Summary
Human immunoglobulin G (IgG) is a plasma-derived antibody product marketed in the US as several BLA-licensed injectable and subcutaneous formulations. The TxGNN model predicts it may be effective for severe nonproliferative diabetic retinopathy, but this rests almost entirely on a computational score. There are 0 clinical trials and 1 publication (a biomarker study of the body’s own IgG, not of IgG as a treatment) behind this specific prediction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the available regulatory data |
| Predicted New Indication | Severe nonproliferative diabetic retinopathy |
| TxGNN Prediction Score | 99.75% |
| Evidence Level | L4 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 20 (listed as BLA licenses) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available for this drug, and its original approved indications are not listed in the source data. Human IgG is a pooled antibody product with immune-modulating properties, so a link to immune-mediated disease is plausible in principle. The evidence pack does not establish a therapeutic mechanism for the retina.
The only supporting study is a 2025 biomarker study. It found that patterns of sugar-chain (Fc glycosylation) changes on a patient’s own serum IgG differ between people with non-proliferative diabetic retinopathy (NPDR), proliferative diabetic retinopathy (PDR), and no retinopathy. This suggests immune-related inflammation may play a role in diabetic retinopathy. It does not show that giving patients human IgG would help.
The high TxGNN score is a computational prediction only. A score of 0.998 should be read as a hypothesis to test, not as evidence of efficacy.
Clinical Trial Evidence
Currently no related clinical trials registered for severe nonproliferative diabetic retinopathy.
For the broader term “diabetic retinopathy”, the search returned three trials. None tested human IgG (an adalimumab uveitis study, a type 1 diabetes beta-cell study, and an aflibercept study in diabetic macular edema), so they do not support this prediction.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 40204274 | 2025 | Biomarker association study | Molecular & Cellular Proteomics | In 160 patients (47 no retinopathy, 51 NPDR, 62 PDR), serum IgG Fc glycosylation patterns were evaluated as diagnostic markers to distinguish NPDR and PDR. It does not test IgG as a treatment. |
Related literature found under the broader “diabetic retinopathy” term is also indirect. It includes a 2025 Mendelian randomization study linking IgG N-glycosylation patterns to diabetic complications (40682148) and an observational study of IgG glycosylation in diabetic retinopathy (33491329). None of these studies evaluated IgG administration.
US Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| BLA125822 | QIVIGY (Kedrion S.p.A.) | Injection, solution | Not listed in source data |
| BLA125668 | Cutaquig (Pfizer Laboratories Div Pfizer Inc) | Solution | Not listed in source data |
| BLA125350 | Hizentra (CSL Behring AG) | Liquid | Not listed in source data |
| BLA125201 | Privigen (CSL Behring AG) | Liquid | Not listed in source data |
These are the first five of 20 licenses. Cutaquig appears twice in the source data and is shown once here.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by a high TxGNN score and one biomarker study of endogenous IgG, with no clinical trial testing human IgG in diabetic retinopathy. Package insert safety data is also missing, so the candidate cannot yet move to safety screening.
To proceed, the following is needed:
- Package insert warnings and contraindications (a blocking gap), plus the approved indications of each product
- Mechanism of action data (for example, from DrugBank) and a stated rationale for how exogenous IgG could act in the retina
- Preclinical or clinical evidence that administering human IgG affects diabetic retinopathy
- Route feasibility for retinal disease, since the listed products are injectable or subcutaneous and route compatibility has not been assessed
This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before any clinical use.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.